enGene initiated with an Overweight at Wells Fargo

Wells Fargo analyst Yanan Zhu initiated coverage of enGene with an Overweight rating and $30 price target. The analyst thinks the company’s lead product candidate in BCG-unresponsive non-muscle invasive bladder cancer has the potential to become the preferred agent in this large market given its potential efficacy and ease-of-use profile. The company has a differentiated non-viral delivery platform targeting mucosal tissues, the analyst tells investors in a research note.